A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Pantoprazole
- Indications Cardiovascular disorders; Coronary artery disease; Myocardial infarction; Peripheral arterial disorders; Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COMPASS; COMPASS CABG
- Sponsors Bayer; Bayer HealthCare
- 28 Dec 2023 Results cost-effectiveness of this regimen in patients with either stable coronary artery disease (CAD) or peripheral artery disease , published in the American Journal of Cardiovascular Drugs
- 13 Jan 2023 Results assessing total events and net clinical benefit of rivaroxaban and aspirin published in the American Heart Journal
- 22 Aug 2022 Status changed from discontinued to completed.